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Abstract
Rationale: The effectiveness of antibiotic molecules in treating Pseudomonas aeruginosa pneumonia is reduced as a result of
the dissemination of bacterial resistance. The existence of bacterial communication systems, such as quorum sensing, has
provided new opportunities of treatment. Lactonases efficiently quench acyl-homoserine lactone-based bacterial quorum
sensing, implicating these enzymes as potential new anti-Pseudomonas drugs that might be evaluated in pneumonia.
Objectives: The aim of the present study was to evaluate the ability of a lactonase called SsoPox-I to reduce the mortality of
a rat P. aeruginosa pneumonia.
Methods: To assess SsoPox-I-mediated quorum quenching, we first measured the activity of the virulence gene lasB, the
synthesis of pyocianin, the proteolytic activity of a bacterial suspension and the formation of biofilm of a PAO1 strain grown
in the presence of lactonase. In an acute lethal model of P. aeruginosa pneumonia in rats, we evaluated the effects of an
early or deferred intra-tracheal treatment with SsoPox-I on the mortality, lung bacterial count and lung damage.
Measurements and Primary Results: SsoPox-I decreased PAO1 lasB virulence gene activity, pyocianin synthesis, proteolytic
activity and biofilm formation. The early use of SsoPox-I reduced the mortality of rats with acute pneumonia from 75% to
20%. Histological lung damage was significantly reduced but the lung bacterial count was not modified by the treatment. A
delayed treatment was associated with a non-significant reduction of mortality.
Conclusion: These results demonstrate the protective effects of lactonase SsoPox-I in P. aeruginosa pneumonia and open
the way for a future therapeutic use.
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Introduction
The dramatic increase of antibiotic resistance in bacterial
isolates from intensive care unit (ICU) patients leads to an
important reduction of therapeutic arsenal [1][2,3][4,5]. Alterna-
tive approaches to combat multidrug-resistant strains are under
extensive research, especially using molecules that can reduce
bacterial expression of virulence factors [1–3][6].
Expression of virulent phenotypes of numerous pathogenic
bacteria is activated when the pathogen senses that a critical
population density has been reached. This ability relates to the
quorum sensing (QS) by which bacteria can sense messenger
molecules thus virulence genes are activated [7]. This communi-
cation ability enables the bacteria to coordinate bacterial
population behavior during the invasion of a host [8][9].
Acyl-Homoserine Lactones (AHLs) are QS molecule messen-
gers used by a large number of Gram-negative bacteria, including
Pseudomonas aeruginosa [10]. These bacteria are able to form
biofilms whose maturation is regulated through QS [11]. Biofilms
have been implicated in antibiotic resistance in chronic P.
aeruginosa infections, primarily through the limitation of the
diffusion of antibiotics into the bacterial colonies [12]. P.
aeruginosa possesses two different AHL-based QS systems: the
LasI/R and RhlI/R with their respective cognate 3-oxo-C12
AHLs and C4 AHLs messenger molecules [13].
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The inhibition of bacterial virulence by targeting QS mecha-
nism can be mediated by (i) the inhibition of the messenger
production, (ii) inhibition of its detection, both known as QS
inhibition/inhibitors [14,15][16], or (iii) the elimination of the
messenger known as quorum quencher (QQ) [17,18] thus
alteration of the P. aeruginosa QS system can attenuate its
virulence. In pneumonia, the efficacy of QS modulation has been
tested at the genomic level with reduction in lethality of infected
animals [9]. Therapeutic management of animals with pneumonia
has been tested with QS inhibitors such as furanones and patulin
showing that these molecules can increase the clearance of
bacteria in mice infected with P. aeruginosa [19,20][21]. Because
some in vitro studies suggest toxicity of furanones and patulin
[22][23], other QS inhibition options are under investigation [24]
among which the use of lactonases or acylases enzymes [10][25].
Lactonases efficiently decrease the production of virulence factors
and biofilm by P. aeruginosa in vitro [26][27], and may therefore
represent an alternative and promising strategy for reducing
bacterial virulence. The efficacy of lactonases to decrease bacterial
virulence has been reported in several hosts [28,29][30]. In a
recent in vivo study on mice with pneumonia [31], the use of a
lactonase-producing P. aeruginosa mutant showed reduced lung
injury and increased survival as compared to the wild strain. These
encouraging results would suggest that the use of lactonases as a
topic therapeutic agent could be effective in improving outcome in
P. aeruginosa pneumonia.
The aim of our work was to test the efficacy of inhaled lactonase
in improving survival of rats with acute P. aeruginosa pneumonia.
To do this, we used an engineered variant of the hyperthermo-
stable lactonase SsoPox (first isolated from the extremophilic
archaea Sulfolobus solfataricus) [32], SsoPox-I, exhibiting a high
stability and an improved ability to hydrolyze 3-oxo-C12 AHLs.
We first tested in vitro the ability of our molecule to reduce, in a
P.aeruginosa PAO1 strain, the virulence gene lasB activity, the
pyocianin synthesis, the proteolytic activity and the biofilm
formation. Thus, we evaluated the effect of SsoPox-I when
delivered early or late intra-tracheally to animals with lungs
infected with P. aeruginosa.
Material and Methods
Protein production & purification
The plasmid encoding SsoPox-I protein was commercially
obtained (GeneArt, Invitrogen; Germany). SsoPox-I protein was
synthesized in E. coli strain BL21(DE3)-pGro7/GroEL (TaKaRa)
in ZYP medium [33] containing 100 mg/ml ampicillin and 34 mg/
ml chloramphenicol as previously described [22]. The proteins
were purified as previously described [34]. Briefly, the culture was
incubated at 70uC for 30 minutes, followed by differential
ammonium sulfate precipitation, dialysis and exclusion size
chromatography. The proteins were quantified using a nanospec-
trophotometer (Nanodrop, ThermoFisher Scientific, France) and
the protein molar extinction coefficient was determined using the
protein primary sequence in PROT-PARAM (ExPASy tool
software) [35]. The protein yield was approximately 10 mg/L
for SsoPox-I, and the identity and purity of the purified protein
was assessed through sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and mass spectrometry (Plateforme
Timone, Marseille, France). The enzymes were stored and used in
phosphate-buffered saline (PBS) (Biomerieux; France).
In vitro experiments
P. aeruginosa culture. P. aeruginosa (strain PA01 ATCC
15692) was grown at 37uC in Luria-Bertani (LB) medium (BD,
France) with shaking (200 rpm). When required, 1.5% bacto agar
was added to solidify the LB.
For in vivo experiments [36], aliquots containing P. aeruginosa
PAO1 strain were thawed and cultured on COS (Biomerieux,
France) (Columbia with 5% Sheep blood) agar plates. Ten fresh
PAO1 colonies were sampled and cultured at 37uC in tryptic soy
broth (TSB, Biomerieux, France) with continuous shaking until the
OD600 nm= 1. Serial dilutions were subsequently performed to
adjust the bacterial amount, and the precise concentrations were
confirmed after plating serial dilutions on the appropriate culture
medium and counting the resulting colonies.
LasB reporter system. A 50-ml aliquot from an 18-hour
culture of P. aeruginosa PAO1 carrying PlasB-luxCDABE (QS
reporter) was added to the wells of a 96-well plate. A ten-fold
dilution series from 50 mg to 0.05 mg of SsoPox-I was added to the
wells containing the P. aeruginosa reporter strain. LB was added
to each well to generate a final volume of 100 ml. The plates were
incubated at 37uC for 90 minutes, with shaking every 10 minutes,
and subsequently analyzed using a Varioskan Flash multimode
plate reader. The luminescence was measured every 10 minutes to
determine the QS reporter activity.
Quantification of pyocianin synthesis. Quantification of
pyocyanin was performed as previously described [37]. Briefly, P.
aeruginosa PAO1 strain was grown in 1 mL of Glycerol-alanine
(GA) minimum medium (10 mL.L21 glycerol, 6 g.L21 L-alanine,
2 g.L21 MgSO4, 0.1 g.L
21 K2HPO4, 0.018 g.L
21 FeSO4) with
and without 14 mM of filtered (0.2 mm pore) SsoPox-I enzyme
during 24 h at 37uC and 450 rpm shaking in 48-well plate
(Greiner Bio-One, Germany). Cells were centrifuged 15 min at
12.000 g and the supernatant was filtered (0.2 mm pore).
Extraction of pyocyanin was performed on 500 mL of supernatant
using 0.56 volume of chloroform and absorbance was subse-
quently measured at 690 nm. Blank assay was realized using
500 mL of culture medium with and without 14 mM of filtered
(0.2 mm pore) SsoPox-I enzyme.
Proteolytic activity. Measurement of the proteolytic activity
was made using azocasein enzymatic assay as previously described
[38]. Briefly, P. aeruginosa PAO1 strain was grown in 200 mL of
LB medium with and without 14 mM of filtered (0.2 mm) SsoPox-I
enzyme during 24 h at 37uC and 450 rpm shaking in 96-well
plate. The SsoPox-I enzyme stock solution being in PBS buffer,
control cultures were supplemented with equivalent PBS quantity.
Cells were centrifuged 15 min at 12.000 g. The reaction was
performed in 0.3 M TrisHCl buffer (pH 7.5) with 50 mL of
azocasein (Sigma, St. Louis, USA) (30 mg.mL21 dissolved in
water) and with 50 mL of culture’s supernatant for a final volume
of 1.5 mL. The reaction was incubated at 37uC for 1 h and
subsequently stopped by addition of 250 mL of 20% (w/v)
trichloroacetic acid (TCA). The blank assay was realized using
50 mL of culture medium with and without 14 mM of filtered
(0.2 mm pore) SsoPox-I enzyme. After centrifugation at 12.000 g
for 10 min, optical density was measured at 366 nm. The
proteolytic activity was defined as the increase in absorbance at
366 nm.h21 per number of cells (OD600).
Biofilm formation assays. Liquid cultures of P. aeruginosa
PAO1 were grown for 18 hours, and subsequently diluted 1:50 in
10% TSB. To examine biofilm susceptibility to SsoPox-I, 100 ml
aliquots were dispensed onto Calgary Biofilm Device 96-well
plates (MBEC Assay for Physiology & Genetics, Innovotech Inc.,
Edmonton, Alberta, Canada). A three-fold dilution series from
50 mg to 0.5 mg of SsoPox-I was added to the wells containing P.
aeruginosa. The plates were incubated for 4 hours with rocking at
120 Hz at 37uC, and subsequently, the MBEC device with
adherent P. aeruginosa biofilms was placed on a fresh 96-well
Lactonase Reduces Pneumonia Mortality in Rats
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plate containing 100 ml of 1% crystal violet dye in each well for
15 minutes. The MBEC device was subsequently washed three
times with 100 ml of water to remove excess dye and allowed to
dry. Crystal violet stain was solubilized from the biofilms after
placing the MBEC device on a 96-well plate with 100 ml of 100%
ethanol in each well. The solubilized crystal violet dye was
measured at 600 nm using a Varioskan Flash multimode plate
reader (Thermo). The optical density at 600 nm was also used to
assess P. aeruginosa PAO1 planktonic growth on the original 96-
well plate to determine the effect of SsoPox-I on P. aeruginosa
planktonic growth.
In vivo experiments
Ethics statement. The experiments and protocols were
performed in accordance with the European law and the French
version of this law details the statutory requirements for the live
animal experiments (articles R214-87 to R215-10 of Code Rural,
law #76–629 from July 10th, 1976/law #2001-464 from May
29th, 2001 (published in JORF on May 31st, 2001)). Consistent
with these laws, the experiments were performed under the direct
control of the researcher authorized through the Pre´fecture-des-
Bouches-du-Rhone Administration (authorization number: 13–
437). The animal experiments were performed in accordance with
‘Animal Research: Reporting In Vivo Experiments’ (ARRIVE
Guidelines http://www.nc3rs.org.uk) and the guidelines of the
Guide for the Care and Use of Laboratory Animals. All animal
experiments were authorized through the National Animal Ethics
Committee («Comite´ National de Re´flexion Ethique sur l9Expe´r-
imentation Animale (Comite´ d9e´thique de Marseille)»). The
experiments were performed in the Faculte´ de Pharmacie-Aix-
Marseille University.
The animals were euthanized with an intra-peritoneal injection
of a lethal dose of thiopental (Panpharma, France).
General procedures. Adult Sprague-Dawley male patho-
gen-free rats, weighing 250 to 300 g, were obtained from SAS
Janvier (Le-Genest-St-Isle, France) and housed in individual
plastic cages (4 animals per cage) in a ventilated pressurized
cabinet (A-BOX 160, Noroit, Reze´, France) with free access to
water and standard diet food. The rats were anesthetized with 5%
Se´voflurane (Abbott, Rungis, France) in 100% oxygen (anesthe-
tizing box, Harvard Apparatus, Les Ulis, France). The trachea was
exposed, and they were intubated using a 16-gauge catheter for
drug and/or bacterial administration. The awakened rats were
housed under the same conditions and weighed daily. At the end
of each experiment, the rats were euthanized with an intra-
peritoneal injection of a lethal dose of thiopental (Panpharma,
France).
Rat tolerance of inhaled SsoPox-I. The tolerance to intra-
tracheal treatment with SsoPox-I was examined in a preliminary
study on 3 groups of animals (n = 3 per group) receiving 250 ml of
SsoPox-I at a concentration of 0.1, 1 or 10 mg/ml and compared
with 5 control animals receiving 250 ml of PBS. After the
treatment, signs of bad tolerance of the molecule were investigated
i.e. shortness of breathing, prostration and atony or weight loss
above 10% from baseline. Spontaneous mortality was also
recorded. One animal from each group was sacrificed after 6,
24 and 48 hours. The remaining animals were sacrificed after
48 hours. Subsequently, the lungs were removed, macroscopically
examined, and preserved in formaldehyde for histological
assessment of lung damage.
Rat respiratory infection model and SsoPox-I
treatment. Three groups of 20 animals were infected through
intra-tracheal inoculation with 250 ml of a PBS solution containing
108 CFU/ml of P. aeruginosa PAO1.
Among the 3 groups of infected rats, one group received
immediately after infection 250 ml of PBS (non-treated group:
NT), while another group was treated with 250 ml of SsoPox-I at a
concentration of 1 mg/ml (immediate treatment group: IT). The
last group received 250 ml of 1 mg/ml SsoPox-I at 3 hours after
infection (deferred treatment group: DT). SsoPox-I and additional
PBS were delivered intra-tracheally using the same anesthetic
procedure as used for the infection.
Lung processing and blood or spleen samples. After
infection, the animals were observed for 2 days, and spontaneous
mortality was examined. Animals’ conditions and clinical status
were checked every 2 hours. Humane endpoints were used during
the survival study. If animals had one of the following signs, they
were anesthetized and euthanized with an intra-peritoneal
injection of a lethal dose of thiopental (Panpharma, France) to
avoid suffering:
– Major dyspnea with noisy breathing and head or neck
movements associated with breathing
– Prostration and atony
– Weight loss.20% of initial body weight.
The remaining rats were euthanized after 48 hours. Subse-
quently, the lungs were removed aseptically. The right lung was
homogenized in PBS for bacterial culture, and the left lung was
preserved for histological analysis. The blood and spleen were
sampled and cultured on agar plates to assess systemic diffusion of
the bacteria.
Histological severity score (HSS). Sections (3 mm thick)
were obtained from the upper, mid and lower parts of the lungs,
including the entire circumference. The sections were stained with
hematoxylin and eosin. A pathologist blinded to the group identity
(H. L.) examined the samples. The HSS was calculated based on
the number of bronchopneumonia lesions (0, no lesions; 1, 30
lesions/lung; 2, $30 lesions/lung; 3, confluent lesions of
bronchopneumonia), as previously reported [39,40].
Statistics
The number of studied animals (20 animals per group) was
calculated based on a mortality reduction from 80% in the NT
group infected with PAO1 to an expected mortality rate of 50% in
the treated groups, with 90% statistical power and a two-sided
alpha value of 0.05. The data were expressed as the means 6
standard deviation (SD) or median [inter-quartile range, IQR]
according to the distribution of the data. Student’s t-test or the
Mann-Whitney rank-sum test were used for inter-group compar-
isons. Kaplan-Meier analysis was performed to evaluate 48-h
mortality. Intergroup differences were evaluated using the log rank
test. The data analysis was performed with SPSS for Windows
(Chicago, IL), version 12.0. A value of p#0.05 was considered
statistically significant.
Results
Protein production & purification
See Fig. S1 in supplementary material.
In vitro experiments
We monitored the lasB activity in a P. aeruginosa PAO1 strain
carrying the PlasB-luxCDABE plasmid. We showed that the
addition of SsoPox-I significantly reduced the levels of lasB activity
(Fig. 1A). Moreover, this inhibition exhibited a dose-dependent
profile with a half inhibition concentration ([C1/2]) of the enzyme
of approximately 0.5 mg/ml (Fig. 1A).
Lactonase Reduces Pneumonia Mortality in Rats
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Pyocyanin secretion was affected by the presence of SsoPox-I
and presented a 4 fold drop in quantity as compared to the control
(Fig. 1B).
Cultures of PAO1 made in presence of 14 mM SsoPox-I showed
after 24 h a clear drop of protease activity followed using
azocasein assay. Protease activity in presence of SsoPox-I was
beyond detection limit (Fig. 1C).
The biofilm assay showed that SsoPox-I reduced biofilm
formation in a dose-dependent manner with a [C1/2],170 mg/
ml (Fig. 1D).
Interestingly, SsoPox-I did not significantly affect the rate of P.
aeruginosa growth. Indeed, even at the highest enzyme dose
(5 mg/ml), the optical density of the cell culture did not
significantly differ from that of the control experiment with no
treatment (Fig. S2).
In vivo experiments
Rat tolerance to inhaled SsoPox-I. The effects of SsoPox-I
treatment on rat tissues were investigated. On the 9 rats that
received SsoPox-I into the trachea, none exhibited any sign of bad
tolerance including in the group that received the highest dose.
The weight curve of treated rats was not different to control
animals and no animal loosed weight. There was no spontaneous
mortality after 48-hours observation in the treated group as well as
in the control group. After sacrifice, the lungs were harvested and
the macroscopic examination showed no signs of injury. Histo-
logical assessment showed that there was no sign of lung damage 6,
24 or 48 hours after the treatment including in the group receiving
the highest dose of SsoPox-I.
Rat respiratory infection model and SsoPox-I
treatment. The influence of SsoPox-I on pulmonary P.
aeruginosa infection was monitored in 3 groups of 20 rats. The
spontaneous mortality rate was 75% (15/20) in the non-treated
Figure 1. Effects of SsoPox-I on PAO1 virulence factors expression and biofilm formation. 1A: lasB activity. The chart shows the lasB
activity in treated cultures, expressed as the percentage of that in untreated controls (no SsoPox-I), and these data represent the average of three
independent experiments, each with three technical replicates. The error bars represent 95% confidence intervals. Student’s t test p,0.05 for SsoPox-
I. T tests were used for the comparison of baseline with the highest dose of enzyme. 1B: pyocianin synthesis. Pyocyanin quantification of P.
aeruginosa PAO1 strain after 24 h growth in GA medium was assessed in presence (black) or absence (gray) of 14 mM of SsoPox-I lactonase. Pyocyanin
quantity was followed at A690 as per number of cells (A600). 1C: proteolytic activity. Proteolytic activity of P. aeruginosa PAO1 strain after 24 h
growth in LB medium was assessed in presence (black) or absence (grey) of 14 mM of SsoPox-I lactonase. Proteolytic activity was measured by the
azocasein assay (A366.h
21) as per number of cells (A600). ND stands for non-detected activity. 1D: biofilm formation. Biofilms were grown in an
MBEC device as described in the methods section. The dose-dependent inhibition of P. aeruginosa biofilm formation through SsoPox-I was observed
and analyzed using Student’s t test p = 0.05 for SsoPox-I.
doi:10.1371/journal.pone.0107125.g001
Lactonase Reduces Pneumonia Mortality in Rats
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e107125
group (NT). When the rats were treated with SsoPox-I (1 mg/ml)
immediately after infection (IT), the mortality rate was significantly
reduced to 20% (4/20) (p=0.0001 vs. NT). The protective effect
of lactonase on mortality was less significant in the deferred
treatment (DT) group, where the treatment was administered at
3 hours after the infection (mortality rate of 50% (10/20) (p=ns
vs. NT) (Fig. 2). However, in the DT group, the mean delay of
mortality was significantly longer than that in the control group
(respectively 2669.5 vs. 1769.2 hours; p = 0.04).
In addition to death, other parameters were monitored during
the infection, including the weight of the animals. We observed
that the loss of body weight, measured from the day of infection
until the day of death, was significantly less important in the IT
group than in the NT group (11.3612 g vs. 20.469.3 g
respectively; p=0.01). The DT group lost 25.661.82 g of body
weight (p = ns vs. NT group).
Notably, consistent with the increased survival rate observed in
the IT group, we also observed that compared with the NT group,
the damage to the lungs of the animals in the IT group was less
significant (Fig. 3), as revealed by a significantly lower HSS (HSS
IT group vs. NT group: 1.2760.6 vs. 2.6460.4; p=0.005). In the
DT group, the mean HSS was not significantly different from that
in the NT group.
Moreover, we also investigated the potential effects of lactonase
treatment on the lung bacterial count, associated with the
increased survival observed in the IT group. We observed that
the lung bacterial count did not significantly differ between the 3
groups (CFU/g of lung in median [inter-quartile range]: 3.36105
[5.6610321.36106] in the NT group; 1.36105 [9.261032106] in
the IT group; and 105 [8.4610427.86105] in the DT group)
(Fig. 4).
Finally, there was no difference concerning the number of
animals with positive blood or spleen culture at the time of death
between the 3 groups (n/tot (%): 8/20 (40%) in the NT group; 7/
20 (35%) in the IT group; 10/20 (50%) in the DT group; p=NS).
Discussion and Conclusions
In the present study, we used both in vitro and in vivo
experiments to show that the lactonase SsoPox-I was able to
decrease the activity of lasB virulence gene, the synthesis of
Figure 2. Forty-eight-hour survival curves for the 3 groups of
animals after infection. The animals were infected with 108 CFU/ml
(2.56107 CFU/rat) of P. aeruginosa PAO1 in the following treatment
groups: non-treated (NT), immediate-treatment (IT) or deferred
treatment (DT) who received treatment with SsoPox-I at 3 hours after
infection.
doi:10.1371/journal.pone.0107125.g002
Figure 3. Lung histological examination after infection.
Pathological mapping of the lungs of non-treated (NT) (A), deferred-
treatment (DT) (B) and immediate-treatment (IT) (C) groups. Photomi-
crographs of the pathological Giemsa staining of the lung sections
(100X). Mean histological severity score (HSS) was 2.6460.4 (mean 6
SD) for the NT group, 1.2760.6 for the IT group (p = 0.005 vs. NT) and
2.3260.4 for the DT group (p =NS vs. NT).
doi:10.1371/journal.pone.0107125.g003
Lactonase Reduces Pneumonia Mortality in Rats
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e107125
pyocianin, the proteolytic activity and the biofilm formation of the
P. aeruginosa PAO1 strain. In addition, the treatment with
SsoPox-I was associated with an important improve in survival in a
rat model of highly lethal acute pneumonia.
Originally, this work focuses on the lactonase SsoPox-I QQ
activity with a design trying to approach clinical settings by giving
the enzyme as a therapeutic drug. Similarly, QS inhibitor
molecules such as furanones have been shown to increase the
bacterial clearance in animal models of P. aeruginosa pneumonia
but data on reduction of mortality are lacking [16] [19,20]. In one
study in mice using indirect demonstration of QQ effects of
lactonases in animal models of pneumonia [31], Migiyama et al.
showed a decrease in mortality and lung damage when animals
were infected with a lactonase-producing P. aeruginosa strain.
The main difference between Migiyama’s study and ours is that we
used a wild strain of P. aeruginosa for infections and we treated
the animals with a synthetic lactonase given after infection as a
therapeutic drug.
The catalytic efficiency and quenching activity of the QS
lactonase SsoPox-I against 3-oxo-C12 AHLs has been previously
improved through protein engineering [32]. While the QS activity
of the wild-type enzyme has been previously demonstrated in vitro
[26], the efficiency of this enzyme in vivo has not been explored.
SsoPox-I inhibits the lasB gene activity, a classical virulence factor
[41], at concentrations as low as 0.5 mg/ml. SsoPox-I is also able
to decrease the pyocianin synthesis as well as the proteolytic
activity of a P.aeruginosa PAO1 strain. Moreover, the effect of
SsoPox-I on P. aeruginosa goes beyond the inhibition of virulence-
associated genes. Indeed, SsoPox-I also inhibited biofilm forma-
tion, albeit at much higher concentrations (170 mg/ml). This
discrepancy in the active dose of the enzyme might reflect the
distinct regulation of biofilm formation and maturation [12] [42].
Indeed, multiple quorum sensing-regulated genes are modulated
without affecting lasRI, rhlRI or the production of N-acyl-L-
homoserine lactones. In particular, the transcriptional regulator
MvfR may contribute more to biofilm formation of P. aeruginosa.
This could explain why in our experiments SsoPox-I seemed to
have a better efficacy on lasB gene down regulation than on
decrease in biofilm formation [43,44].
We further investigated the potential consequences of the
observed in vitro effects. For this, we used an acute lethal model
of P. aeruginosa pneumonia. Our model was consistent with
previous ones showing a high and early lethality within the 24–48
first hours [45–47]. On histological analysis, the lungs of
untreated animals exhibited important and confluent lesions of
broncho-pneumonia arguing for the correlation between death
and severity of pneumonia. In addition, nearly one half of the
animals had bacteremia which probably contributed to the high
mortality rate. In this model, SsoPox-I significantly decreased the
mortality rate from 75% in the non-treated group to 20% in the
group treated immediately after infection. This observation is
consistent with the dramatic reduction in the lung damage
observed in the treated group. The results are also consistent with
previous studies showing that infections with QS-deleted strains
of P. aeruginosa were less severe in several infection models
[48][49].
SsoPox-I did not significantly reduce lung lesions and rat
mortality when administrated at 3 hours after the onset of
infection. This ineffectiveness might be due to the use of a highly
lethal model of infection (death in 48 hours). The preventive
action of SsoPox-I might be higher than its curative effect as
previously observed for QSI [22]. QS is indeed under a positive
retro-control regulation [50]: when the bacterial quorum is
reached, the inhibition of QS is more difficult because of the
self-stimulating properties of bacteria.
In our study, the innovative molecule SsoPox-I was adminis-
tered intra-tracheally within the 3 first hours of infection. This
design was chosen to approach clinical preventive therapeutic
methods used in patients at risk for P. aeruginosa infections, such
as ICU patients. However, our model did not totally mimic clinical
settings primarily because of the high amount of bacteria given in
one inoculation.
No difference in the lung bacterial burden was observed
between the control group and the 2 treated groups regardless the
time of administration of the molecule. While surprising, these
results are consistent with our in vitro findings on bacterial
cultures in which lactonase adjunction to the media did not
influence P. aeruginosa growth. These results agree with those of
Migiyama et al. [31] who showed similar bacterial count with
animals infected with wild-type P. aeruginosa and their
lactonase-producing mutant strain. It remains however unknown
whether the improved survival could be due to a less invasive
activity of the microorganism towards the lung parenchyma and/
or to change in the host-pathogen interaction regardless the
bacterial load.
In summary, SsoPox-I presents several properties that could
increase the therapeutic arsenal, particularly in the field of
nosocomial pneumonia. In contrast to antibiotics, quorum-
quenching strategies do not impose drastic selection pressure on
bacterial survival. Therefore, treatments with lactonases such as
SsoPox-I might not or only slightly, promote the emergence of
resistance [7][51]. Interestingly, due to their ability to reduce
biofilm formation, lactonases could restore susceptibility to
antibiotics in drug-resistant strains as previously observed with
tobramycin in animal models [52]. Because of its mechanisms of
action involving a modulation of the QS, azythromycin has been
recently shown in a randomized controlled trial to reduce the
incidence of ventilator-acquired pneumonia in pseudomonas
colonized patients [53] showing the growing interest of QS
inhibitors in clinics.
To conclude, our results open the way to further investigations
assessing SsoPox-I as a possible tool in antimicrobial strategy.
Figure 4. Lung bacterial count after infection. The lung bacterial
count was adjusted according to the lung weight. The box plots limits
represent the 25th and 75th percentiles, and the bars represent the 5th
and 95th percentiles. The median is represented as a horizontal line.
NT = non-treated group; IT = immediate treatment group; DT =
deferred treatment group.
doi:10.1371/journal.pone.0107125.g004
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Supporting Information
Figure S1 SDS-PAGE of SsoPox-I. Twenty-five mg of SsoPox-I
(left band) were deposited next to aMolecular weight Marker (MwM,
right panel) (Mulicolor broad range protein ladder, Euromedex).
(TIF)
Figure S2 The growth of P. aeruginosa in the presence of
SsoPox-I.A small decrease in P. aeruginosa growth was observed at
the highest concentration of SsoPox-I; however, this effect was not
significant (Student’s t test p=0.67). The chart shows percentage of
controls (no SsoPox-I) and represents the data obtained from four
independent experiments, each performed with three technical
replicates. The error bars represent 95% confidence intervals.
(TIF)
Checklist S1 Arrive guidelines.
(PDF)
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